Storia in 2 fonti

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

Medtronic (MDT) to report Q4 2026 results on 6/3, expected revenue of $9.61B & EPS of $1.55. Recent acquisition of SPR Therapeutics adds to neuromodulation business. Analyst ratings show mixed opinions.

Raccontata da

benzinga.com

morningstar.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mesi fa

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

originale

morningstar.com1 mesi fa

Medtronic Up Nearly 5%, on Pace for Largest Percent Increase Since November 2020 — Data Talk

Medtronic Plc (MDT) is currently at $77.42, up $3.67 or 4.98%

Leggi questa versione → originale

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

Confronto fonti

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

Medtronic Up Nearly 5%, on Pace for Largest Percent Increase Since November 2020 — Data Talk

Timeline cronologica

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

How To Earn $500 A Month From Medtronic Stock After Q4 Earnings - Medtronic (NYSE:MDT)

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

Confronto fonti

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

Medtronic Up Nearly 5%, on Pace for Largest Percent Increase Since November 2020 — Data Talk

Timeline cronologica

Medtronic to Report Fiscal Fourth Quarter Results; These Most Accurate Analysts Revise Forecasts Ahead Of

How To Earn $500 A Month From Medtronic Stock After Q4 Earnings - Medtronic (NYSE:MDT)

Medtronic Up Nearly 5%, on Pace for Largest Percent Increase Since November 2020 — Data Talk

Why Is Medtronic Stock Gaining Wednesday? - Medtronic (NYSE:MDT)

Wall Street May Be Mispricing Medtronic, Analyst Says - Medtronic (NYSE:MDT)